These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 31640814)

  • 1. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
    Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
    J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
    Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
    Molecules; 2019 May; 24(11):. PubMed ID: 31151293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity.
    Tooyserkani R; Rasaee MJ; Bandehpour M; W P M Löwik D
    J Drug Target; 2021 Aug; 29(7):771-782. PubMed ID: 33478285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
    Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
    Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.
    Liu H; Liu Y; Zhao Z; Li Y; Mustafa B; Chen Z; Barve A; Jain A; Yao X; Li G; Cheng K
    Front Immunol; 2022; 13():838966. PubMed ID: 35444660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
    Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
    Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
    Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
    Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
    Zhai W; Zhou X; Du J; Gao Y
    Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design.
    Zou S; Liu J; Sun Z; Feng X; Wang Z; Jin Y; Yang Z
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):185-193. PubMed ID: 31745591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
    Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
    Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
    Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
    Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
    Liang Y; Luo H; Li X; Liu S; Habib A; Liu B; Huang J; Wang J; Yi H; Hu B; Zheng L; Xie J; Zhu N
    Front Immunol; 2024; 15():1367040. PubMed ID: 38745661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
    Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
    J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.